27/03/2024

SOLVE Project Officially Launched at Kick-Off Meeting

March 25 and 26, 2024, the Kick-Off Meeting (KOM) marked the official launch of the EU-funded SOLVE project, an ambitious initiative aimed at developing next-generation vaccine platforms to combat SARS-CoV-2, including its emerging variants. Bringing together leading scientists, clinicians, and public health experts from across Europe, the meeting outlined SOLVE’s groundbreaking objectives and set the stage for its collaborative efforts over the next five years.

Breaking New Ground in Vaccine Innovation

The SOLVE project is dedicated to designing and evaluating innovative vaccine platforms, including technologies such as:

Collaborative Framework

At the heart of SOLVE lies a well-structured framework of nine interconnected Work Packages (WP), each focusing on a critical aspect of vaccine development and evaluation. The KOM highlighted the contributions of key WPs, such as vaccine design and preclinical evaluation (WP1-WP2), preparation for human clinical trials (WP3), immunological profiling (WP4-WP6), and public health impact studies (WP8). Together, these components form a comprehensive roadmap toward next-generation vaccines.

The Roadmap for SOLVE

The first milestones involve finalizing vaccine designs and launching preclinical trials by mid-2024. By 2025, the project aims to commence Experimental Medicine Trials (EMT), setting a strong foundation for achieving its goals. The KOM underscored the importance of scientific collaboration, regulatory alignment, and public health engagement to ensure success.

With the momentum gained at the Kick-Off Meeting, the SOLVE consortium is well-positioned to deliver on its mission of advancing vaccine science and addressing the global challenge of COVID-19.